Castle Biosciences (CSTL) Fundamental Analysis: Revenue, Earnings & Valuation

6.06 / 10

Outperform

Fundamentally, CSTL earns an Outperform rating with a 6.1/10 score. Positive drivers include Cash‑MV, Asset‑MV, Revenue‑MV and YoY revenue growth, while PB‑ROE and gross profit margin lag. Overall outlook is cautiously optimistic.

Analysis Checks(8/10)

Revenue-MV

Value-0.59

Score3/3

Weight41.39%

1M Return9.01%

Total operating revenue (YoY growth rate %)

Value3.66

Score3/3

Weight5.11%

1M Return1.54%

Inventory turnover ratio

Value7.73

Score2/3

Weight-3.69%

1M Return-1.21%

Gross profit margin (%)

Value79.37

Score0/3

Weight-19.19%

1M Return-7.24%

PB-ROE

Value0.87

Score0/3

Weight13.20%

1M Return3.23%

Income tax / Total profit (%)

Value18.15

Score2/3

Weight3.51%

1M Return1.04%

Fixed assets turnover ratio

Value3.94

Score2/3

Weight-1.75%

1M Return-0.51%

Cost of sales ratio (%)

Value20.63

Score2/3

Weight-12.60%

1M Return-4.42%

Asset-MV

Value-0.55

Score2/3

Weight50.72%

1M Return12.22%

Cash-MV

Value-0.31

Score2/3

Weight23.30%

1M Return5.94%

Is CSTL undervalued or overvalued?

CSTL scores 6.06/10 on fundamentals and holds a Discounted valuation at present. Backed by its -5.21% ROE, -7.02% net margin, -30.50 P/E ratio, 1.56 P/B ratio, and -225.76% earnings growth, these metrics solidify its Outperform investment rating.